Pantoprazole

Pantoprazole is a substituted benzimidazole proton pump inhibitor (PPI) that irreversibly binds to and inhibits the hydrogen-potassium ATPase enzyme system (the "proton pump") in the gastric parietal cells — the mechanism responsible for secreting acid into the stomach. By blocking this final step in acid production, pantoprazole substantially reduces gastric acid output regardless of the stimulus (food, caffeine, stress, histamine).¹

Pantoprazole has a relatively short plasma half-life of approximately 1 hour, but its effects on acid suppression last much longer (up to 24 hours) because of its irreversible binding to the proton pump. New pumps must be synthesized before acid production fully recovers.

Erosive esophagitis — healing and symptomatic relief, in adults and children 5 years and older. Short-term treatment up to 8 weeks (may extend to 16 weeks for non-responders).

Maintenance of healing of erosive esophagitis — long-term maintenance after initial healing.

Pathological hypersecretory conditions including Zollinger-Ellison syndrome.¹

Off-label uses: Pantoprazole is very widely used off-label for gastroesophageal reflux disease (GERD), non-erosive reflux disease, dyspepsia, peptic ulcer disease, and as gastroprotection in patients taking NSAIDs.

For erosive esophagitis: 40 mg once daily for 8 weeks, taken 30 minutes before a meal. Tablets should be swallowed whole — not split, crushed, or chewed.¹

Oral delayed-release tablets. Also available as intravenous formulation for hospital use.

Store at controlled room temperature (68°F to 77°F / 20°C to 25°C). Do not split, crush, or chew tablets — the enteric coating is essential for proper delivery.¹

Key considerations from the FDA label and clinical research:¹

• Magnesium deficiency: Long-term PPI use (generally more than 1 year) has been associated with hypomagnesemia (low magnesium), which can cause muscle spasms, irregular heartbeat, and seizures. Magnesium levels should be checked before starting long-term PPI therapy and monitored periodically. Users supplementing with magnesium should be aware of this interaction.
• Bone fractures: Long-term PPI use has been associated with increased risk of osteoporosis-related fractures of the hip, wrist, and spine, particularly at higher doses and with use exceeding 1 year. Calcium and vitamin D supplementation may be relevant for long-term users.
• Vitamin B12 deficiency: Gastric acid is needed for proper absorption of vitamin B12 from food. Long-term PPI use can reduce B12 absorption, potentially leading to deficiency over time.
• Iron absorption: Reduced stomach acid impairs the absorption of non-heme iron (from plant sources and iron supplements). Relevant for users taking iron supplements — separate by at least 2 hours.
• Clostridium difficile: PPI use has been associated with increased risk of C. difficile-associated diarrhea, particularly in hospitalized patients.
• Drug interactions: Pantoprazole can reduce absorption of medications that require an acidic environment — atazanavir, rilpivirine, ketoconazole, itraconazole. It can also affect methotrexate levels.
• Levothyroxine: PPI use may reduce levothyroxine absorption; thyroid function should be monitored in patients on both medications.
• Duration of use: The FDA label indicates short-term use (8 weeks). Long-term use is common in clinical practice but should be periodically reassessed — many patients can be stepped down to lower doses or H2 blockers for maintenance.